Cryoglobulinemia Type II (Mixed Cryoglobulinemia) — HCV Eradication & Immune Complex Vasculitis Management

Type II Cryoglobulinemia is a type of mixed cryoglobulinemia where the blood contains immune complexes formed between a monoclonal IgM antibody (which has rheumatoid factor activity — meaning it binds to other antibodies) and polyclonal IgG antibodies. These immune complexes precipitate (solidify) when the body cools, deposit in small blood vessel walls, activate the complement system, and trigger a small-vessel vasculitis affecting skin, kidneys, peripheral nerves, and joints. Over 90% of Type II cases are caused by chronic hepatitis C virus (HCV) infection driving the B-cell clone that produces the monoclonal IgM.

Hepatitis C virus directly infects B-lymphocytes in addition to liver cells, chronically stimulating them and driving clonal expansion. Over years of chronic HCV infection, specific B-cell clones expand and produce a monoclonal IgM antibody with rheumatoid factor activity. This IgM forms immune complexes with polyclonal IgG, which precipitate in cold temperatures as the Type II cryoglobulin. The immune complexes deposit in small blood vessels, causing the vasculitis. HCV RNA is found at high concentration within the cryoprecipitate itself, demonstrating the direct link. Eradicating HCV with modern antiviral therapy removes the B-cell-stimulating antigen and resolves cryoglobulinemia in most patients.

Meltzer's triad is the classic clinical presentation of mixed cryoglobulinemia, consisting of three symptoms: (1) palpable purpura — raised, non-blanching purple spots on the lower legs from small vessel vasculitis; (2) arthralgia — joint pain without destructive joint disease; and (3) weakness — generalised fatigue and muscle weakness. All three together are present in about one-third of Type II cryoglobulinemia patients. Even one or two features should prompt cryoglobulin testing and HCV serology. The presence of purpura alone — particularly on the lower legs — in an adult should trigger investigation for cryoglobulinemia.

In most cases, yes. Modern direct-acting antiviral (DAA) therapy eradicates HCV in over 95% of patients within 8–12 weeks of treatment. After HCV is eliminated (sustained virological response, SVR), the B-cell clone that was producing the cryoglobulin loses its stimulus and regresses. Over weeks to months after achieving SVR, most patients see: cryocrit falling, complement C4 rising toward normal, purpura resolving, joint symptoms improving, and renal function stabilising or improving. However, a proportion of patients — particularly those with long-standing disease and an established autonomous B-cell clone — have persistent cryoglobulinemia after SVR and may require additional B-cell-targeted therapy (rituximab).

Direct-acting antivirals are oral medications that directly target specific steps in the HCV replication cycle — blocking the NS3/4A protease, NS5A replication complex, or NS5B polymerase. Modern pan-genotypic DAA combinations such as sofosbuvir + velpatasvir (Epclusa) or glecaprevir + pibrentasvir (Maviret) are effective against all HCV genotypes in an 8–12 week course with SVR rates exceeding 95–97%. They are well-tolerated with few side effects and represent one of the most successful antiviral developments in the history of medicine. In HCV-associated Type II cryoglobulinemia, DAA therapy is the primary treatment — immunosuppression is only added when vasculitis is severe and immediately organ-threatening.

Rituximab is an anti-CD20 antibody that depletes B-cells, including the B-cell clone producing the monoclonal IgM-RF cryoglobulin. It is used in Type II cryoglobulinemia for: severe vasculitis manifestations that are immediately organ-threatening (rapidly progressive glomerulonephritis, severe neuropathy, extensive skin necrosis); patients whose vasculitis remains active after achieving HCV SVR (persistent autonomous B-cell clone); and HCV-negative Type II cryoglobulinemia where antiviral therapy is not applicable. Rituximab is combined with, not instead of, DAA antiviral therapy in HCV-positive patients. It produces rapid clinical improvement within 2–4 weeks in most patients.

Yes — renal involvement occurs in approximately 25–30% of Type II cryoglobulinemia patients and is one of the most serious complications. Immune complex deposition in the kidney glomeruli causes membranoproliferative glomerulonephritis (MPGN) — presenting with haematuria (blood in urine), significant proteinuria, hypertension, and declining kidney function. Renal biopsy with immunofluorescence shows IgM, IgG, and C3 deposits in glomerular capillaries and mesangium. Treatment with DAA therapy and rituximab (for severe cases) typically stabilises or improves renal function, though recovery of established renal scarring is limited.

Yes — long-standing HCV-associated Type II cryoglobulinemia carries an approximately 10-fold increased risk of B-cell lymphoma compared to the general population, predominantly marginal zone lymphoma (splenic or nodal). This reflects the underlying B-cell clonal expansion driven by chronic HCV-related B-cell stimulation that has not been controlled. HCV eradication with DAA therapy reduces lymphoma risk over time by eliminating the B-cell-stimulating antigen. All patients with Type II cryoglobulinemia — even after achieving HCV SVR — require periodic haematology review to monitor for lymphoma emergence with blood counts, clinical examination, and imaging when indicated.

Yes. CancerFax connects Type II cryoglobulinemia patients with specialist hepatologists, haematologists, and nephrologists — reviewing HCV genotyping results, cryoglobulin characterisation, complement levels, renal function studies, and vasculitis extent. We provide guidance on optimal pan-genotypic DAA regimen selection, rituximab access for severe vasculitis, renal MPGN co-management, and B-cell lymphoma surveillance planning. We coordinate with specialist hepatology, vasculitis, and haematology centres in India, Germany, South Korea, the UAE, and other countries internationally.